CPA1: Potential Drug Target and Biomarker for Pancreatic Cancer and Other Diseases

Target Name: CPA1

NCBI ID: G1357

CPA1

CPA1: Potential Drug Target and Biomarker for Pancreatic Cancer and Other Diseases

CPA1 (Carboxypeptidase A1) is a protein that is expressed in the pancreas, a gland located behind the stomach that is responsible for producing hormones and digestive enzymes. The pancreas is also the site where enzymes such as CPA1 are produced to break down proteins into smaller peptides.

CPA1 is a member of the superfamily of trypsin-like enzymes, which are a group of enzymes that are involved in the processing of proteins. These enzymes belong to the serine proteases family 11 and are characterized by the presence of a specific active site that is involved in the catalytic mechanism of the enzyme.

CPA1 is expressed in the pancreas and is involved in the breakdown of proteins that are essential for normal physiological function. It is expressed at high levels in the pancreas and is responsible for breaking down a wide variety of proteins, including caseins, which are the main components of milk.

CPA1 is also involved in the production of hormones in the pancreas. It is a key enzyme in the production of somatostatin, a hormone that regulates various physiological processes in the body, including satiety and hunger.

CPA1 is a potential drug target for several diseases. One of the main reasons for its potential as a drug target is its involvement in the production of hormones that regulate various physiological processes in the body. For example, CPA1 is involved in the production of somatostatin, which is a hormone that plays a key role in the regulation of appetite and satiety.

CPA1 is also involved in the production of other hormones that are important for normal physiological function. For example, it is involved in the production of prohormone growth hormone (GH), which is important for the growth and development of tissues in the body. It is also involved in the production of insulin, which is a hormone that regulates blood sugar levels.

CPA1 is also potential drug target for its role in the development of certain diseases. For example, it is involved in the production of caseins, which are the main components of milk. In the development of milk-related diseases, such as mastitis, CPA1 has been shown to play a key role in the production of caseins and may be a potential drug target.

CPA1 is also a potential biomarker for several diseases. For example, it is a useful biomarker for the diagnosis of pancreatic cancer, as its production is often reduced in these types of cancer. It is also a potential biomarker for other diseases, such as diabetes, as its production is often increased in individuals with these conditions.

In conclusion, CPA1 is a protein that is expressed in the pancreas and is involved in the breakdown of proteins that are essential for normal physiological function. It is also involved in the production of hormones that regulate various physiological processes in the body, including satiety and hunger. As a result, CPA1 is a potential drug target and a useful biomarker for several diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments for diseases where it is involved.

Protein Name: Carboxypeptidase A1

Functions: Carboxypeptidase that catalyzes the release of a C-terminal amino acid, but has little or no action with -Asp, -Glu, -Arg, -Lys or -Pro (PubMed:8806703). Catalyzes the conversion of leukotriene C4 to leukotriene F4 via the hydrolysis of an amide bond (By similarity)

The "CPA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets